Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

Investigators used 3-dimensional quantitative computed tomography to more accurately assess patients’ bone mineral density.

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...

Research indicates that vitamin D supplementation during pregnancy positively impacts children's bone health and lean mass, ...

Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

Cantor analysts said they found the bone mineral density changes when reviewing supplemental data that was published along ...

Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday after a ...

Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes ...